Business Description
Oruka Therapeutics Inc
NAICS : 541720
SIC : 2834
ISIN : US6876041087
Total Employee Number:
68Compare
Compare
Traded in other countries / regions
ORKA.USAHQ1.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2024-09-03Description
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 343.11 | |||||
Equity-to-Asset | 0.98 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -25.04 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 22.28 | |||||
9-Day RSI | 32.19 | |||||
14-Day RSI | 40.56 | |||||
3-1 Month Momentum % | 74.74 | |||||
6-1 Month Momentum % | 186.46 | |||||
12-1 Month Momentum % | 520.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 38.51 | |||||
Quick Ratio | 38.51 | |||||
Cash Ratio | 38.03 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -22.95 | |||||
ROA % | -22.15 | |||||
ROIC % | -107.91 | |||||
ROC (Joel Greenblatt) % | -6486.53 | |||||
ROCE % | -25.15 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 5.03 | |||||
Price-to-Tangible-Book | 5.03 | |||||
EV-to-EBIT | -35.49 | |||||
EV-to-EBITDA | -35.52 | |||||
EV-to-FCF | -51.36 | |||||
| Price-to-Net-Current-Asset-Value | 6.53 | |||||
| Price-to-Net-Cash | 6.62 | |||||
Earnings Yield (Greenblatt) % | -2.82 | |||||
FCF Yield % | -1.67 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ORKA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Oruka Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.03 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 84.65 | ||
| 14-Day RSI | 40.56 | ||
| 14-Day ATR ($) | 5.43399 | ||
| 20-Day SMA ($) | 102.7585 | ||
| 12-1 Month Momentum % | 520.24 | ||
| 52-Week Range ($) | 14.665 - 115.515 | ||
| Shares Outstanding (Mil) | 66.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Oruka Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Oruka Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 70 days | ||
| Second quarter earnings results for 2026 | 2026-08-10 | 98.82 (-0.97%) | ||
| Guidance call for 2026 | 2026-06-03 15:45 | 55.23 (+1.56%) | ||
| General meeting for 2025 | 2026-06-02 08:00 | 55.01 (-4.38%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 64.65 (-0.60%) | ||
| Interim EVERLAST-A Data Presentation | 2026-04-27 08:00 | 69.03 (+1.75%) | ||
| Annual report for 2025 | 2026-03-12 | 34.41 (+2.72%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-12 | 34.41 (+2.72%) | ||
| The 44th Annual J.P. Morgan Healthcare Conference | 2026-01-15 09:00 | 32.00 (+0.95%) | ||
| Jefferies Global Healthcare Conference | 2025-11-18 14:00 | 28.23 (+5.93%) |
Show
Entries
Oruka Therapeutics Inc Frequently Asked Questions
What is Oruka Therapeutics Inc(ORKA)'s stock price today?
The current price of ORKA is $91.63. The 52 week high of ORKA is $115.52 and 52 week low is $14.67.
When is next earnings date of Oruka Therapeutics Inc(ORKA)?
The next earnings date of Oruka Therapeutics Inc(ORKA) is 2026-11-12 Est..
Does Oruka Therapeutics Inc(ORKA) pay dividends? If so, how much?
Oruka Therapeutics Inc(ORKA) does not pay dividend.
Guru Commentaries on NAS:ORKA
Cable Car Capital
Bullish
2025 Q1
Cable Car Capital, LP
· 204 holdings
What the manager wrote
We believe the merger with Oruka Therapeutics (ORKA) represents a strong opportunity in the biotech sector. The transaction valuation is expected to be validated by subsequent financing, which should ensure a superior outcome for shareholders compared to liquidation. Our involvement in the merger process and the strategic focus on returning capital to investors during the current downcycle further solidifies our positive outlook on ORKA's potential. The historical patterns in biotech cycles suggest that acquiring stakes in companies like ORKA, which may be trading at negative enterprise value, can yield significant returns as the market recovers.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Oruka Therapeutics Inc
Oruka Therapeutics (ORKA) Advances Clinical Trials Amid High Valuation and Mixed Insider Signals
Aug 10, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers